Filing Details
- Accession Number:
- 0001093557-25-000062
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-11 19:17:00
- Reporting Period:
- 2025-03-08
- Filing Date:
- 2025-03-11
- Accepted Time:
- 2025-03-11 19:17:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1093557 | Dexcom Inc | DXCM | Surgical & Medical Instruments & Apparatus (3841) | 330857544 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1681267 | M Jereme Sylvain | 6340 Sequence Drive San Diego CA 92121 | Evp, Chief Financal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-08 | 35,906 | $0.00 | 119,684 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2025-03-08 | 22,798 | $0.00 | 142,482 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2025-03-10 | 2,670 | $73.22 | 139,812 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-10 | 3,203 | $74.04 | 136,609 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-10 | 1,127 | $74.70 | 135,482 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
- Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
- This transaction was executed in multiple trades at prices ranging from $72.56 to $73.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- This transaction was executed in multiple trades at prices ranging from $73.56 to $74.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- This transaction was executed in multiple trades at prices ranging from $74.61 to $74.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 252 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025.
Billionaire Hedge Funds
